230 related articles for article (PubMed ID: 32969780)
1. Sulforhodamine B and exogenous surfactant effects on alveolar surface tension under acute respiratory distress syndrome conditions.
Nguyen TL; Perlman CE
J Appl Physiol (1985); 2020 Dec; 129(6):1505-1513. PubMed ID: 32969780
[TBL] [Abstract][Full Text] [Related]
2. Intravenous sulforhodamine B reduces alveolar surface tension, improves oxygenation, and reduces ventilation injury in a respiratory distress model.
Wu Y; Nguyen TL; Perlman CE
J Appl Physiol (1985); 2021 May; 130(5):1305-1316. PubMed ID: 33211596
[TBL] [Abstract][Full Text] [Related]
3. Tracheal acid or surfactant instillation raises alveolar surface tension.
Nguyen TL; Perlman CE
J Appl Physiol (1985); 2018 Nov; 125(5):1357-1367. PubMed ID: 29771610
[TBL] [Abstract][Full Text] [Related]
4. Surface tension in situ in flooded alveolus unaltered by albumin.
Kharge AB; Wu Y; Perlman CE
J Appl Physiol (1985); 2014 Sep; 117(5):440-51. PubMed ID: 24970853
[TBL] [Abstract][Full Text] [Related]
5. Sulforhodamine B interacts with albumin to lower surface tension and protect against ventilation injury of flooded alveoli.
Kharge AB; Wu Y; Perlman CE
J Appl Physiol (1985); 2015 Feb; 118(3):355-64. PubMed ID: 25414246
[TBL] [Abstract][Full Text] [Related]
6. Lung ventilation injures areas with discrete alveolar flooding, in a surface tension-dependent fashion.
Wu Y; Kharge AB; Perlman CE
J Appl Physiol (1985); 2014 Oct; 117(7):788-96. PubMed ID: 25080924
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of surfactant therapy of ARDS induced by hydrochloric acid aspiration followed by ventilator-induced lung injury - an animal study.
Mikolka P; Kosutova P; Kolomaznik M; Mateffy S; Nemcova N; Mokra D; Calkovska A
Physiol Res; 2022 Dec; 71(S2):S237-S249. PubMed ID: 36647912
[TBL] [Abstract][Full Text] [Related]
8. Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome.
Seeds MC; Grier BL; Suckling BN; Safta AM; Long DL; Waite BM; Morris PE; Hite RD
Am J Med Sci; 2012 Jun; 343(6):446-51. PubMed ID: 22173044
[TBL] [Abstract][Full Text] [Related]
9. Lodixanol inhibits exogenous surfactant therapy in rats with acute respiratory distress syndrome.
Kesecioglu J; Schultz MJ; Haitsma JJ; den Heeten GJ; Lachmann B
Eur Respir J; 2002 May; 19(5):820-6. PubMed ID: 12030719
[TBL] [Abstract][Full Text] [Related]
10. Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome.
Silva JD; de Oliveira GP; Samary Cdos S; Araujo CC; Padilha Gde A; Costa e Silva Filho F; da Silva RT; Einicker-Lamas M; Morales MM; Capelozzi VL; da Silva VM; Lima LM; Barreiro EJ; Diaz BL; Pelosi P; Silva PL; Garcia CS; Rocco PR
Cell Physiol Biochem; 2016; 38(2):821-35. PubMed ID: 26905925
[TBL] [Abstract][Full Text] [Related]
11. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
Cattel F; Giordano S; Bertiond C; Lupia T; Corcione S; Scaldaferri M; Angelone L; De Rosa FG
Respir Physiol Neurobiol; 2021 Jun; 288():103645. PubMed ID: 33657448
[TBL] [Abstract][Full Text] [Related]
12. Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
Wang Z; Chang Y; Schwan AL; Notter RH
Am J Respir Cell Mol Biol; 2007 Oct; 37(4):387-94. PubMed ID: 17556674
[TBL] [Abstract][Full Text] [Related]
13. Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?
Dushianthan A; Cusack R; Goss V; Postle AD; Grocott MP
Crit Care; 2012 Nov; 16(6):238. PubMed ID: 23171712
[TBL] [Abstract][Full Text] [Related]
14. Surfactant therapy for acute lung injury and acute respiratory distress syndrome.
Raghavendran K; Willson D; Notter RH
Crit Care Clin; 2011 Jul; 27(3):525-59. PubMed ID: 21742216
[TBL] [Abstract][Full Text] [Related]
15. Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome.
Zhu GF; Sun B; Niu SF; Cai YY; Lin K; Lindwall R; Robertson B
Am J Respir Crit Care Med; 1998 Aug; 158(2):437-43. PubMed ID: 9700118
[TBL] [Abstract][Full Text] [Related]
16. Exogenous surfactant in paediatric Acute Lung Injury and Acute Respiratory Distress Syndrome.
Playfor SD; Nootigattu VK
Curr Drug Saf; 2006 May; 1(2):159-68. PubMed ID: 18690927
[TBL] [Abstract][Full Text] [Related]
17. Synthetic lung surfactants containing SP-B and SP-C peptides plus novel phospholipase-resistant lipids or glycerophospholipids.
Notter RH; Gupta R; Schwan AL; Wang Z; Shkoor MG; Walther FJ
PeerJ; 2016; 4():e2635. PubMed ID: 27812430
[TBL] [Abstract][Full Text] [Related]
18. Bile acids cause secretory phospholipase A2 activity enhancement, revertible by exogenous surfactant administration.
De Luca D; Minucci A; Zecca E; Piastra M; Pietrini D; Carnielli VP; Zuppi C; Tridente A; Conti G; Capoluongo ED
Intensive Care Med; 2009 Feb; 35(2):321-6. PubMed ID: 18853138
[TBL] [Abstract][Full Text] [Related]
19. 18:1/18:1-Dioleoyl-phosphatidylglycerol prevents alveolar epithelial apoptosis and profibrotic stimulus in a neonatal piglet model of acute respiratory distress syndrome.
Preuß S; Scheiermann J; Stadelmann S; Omam FD; Winoto-Morbach S; Lex D; von Bismarck P; Adam-Klages S; Knerlich-Lukoschus F; Wesch D; Held-Feindt J; Uhlig S; Schütze S; Krause MF
Pulm Pharmacol Ther; 2014 Jun; 28(1):25-34. PubMed ID: 24140177
[TBL] [Abstract][Full Text] [Related]
20. Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials.
Meng H; Sun Y; Lu J; Fu S; Meng Z; Scott M; Li Q
J Cardiothorac Vasc Anesth; 2012 Oct; 26(5):849-56. PubMed ID: 22265270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
